Summary
AstraZeneca has halted a stage 2 drug trial for its lung cancer treatment, volrustomig, following a previous decision to stop a heart disease treatment trial a month prior.
AstraZeneca Discontinues Lung Cancer Treatment Trial for Volrustomig
HyperFast News
Related news
AstraZeneca's breast cancer drug fails to meet goal in late-stage trial
18 Sept 2026, 10:47 pm · News
AstraZeneca's 'Magic' Faces Rare Test After Trial Failure, Share Slide
18 Sept 2026, 10:47 pm · News
AstraZeneca shares slide after Ionis-partnered drug Wainua fails late-stage heart disease trial
18 Sept 2026, 10:47 pm · News
